Ammonia n 13
Ammonia n 13 is a small molecule pharmaceutical. Ammonia n 13 was first approved as Ammonia n 13 on 2007-08-23.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Ammonia n-13
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| AMMONIA N 13 | Feinstein Institutes for Medical Research | N-022119 RX | 2007-08-23 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| ammonia inhalants | unapproved drug other | 2023-04-27 |
| ammonia n 13 | ANDA | 2023-02-06 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
17 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Heart failure | D006333 | EFO_0003144 | I50 | — | — | — | 1 | — | 1 |
| Pulmonary arterial hypertension | D000081029 | — | — | — | 1 | — | 1 | ||
| Familial primary pulmonary hypertension | D065627 | I27.0 | — | — | — | 1 | — | 1 |
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Coronary artery disease | D003324 | I25.1 | 1 | — | — | — | 3 | 4 | |
| Heart diseases | D006331 | EFO_0003777 | I51.9 | 1 | — | — | — | 1 | 2 |
| Cardiomyopathies | D009202 | EFO_0000318 | I42 | 1 | — | — | — | 1 | 2 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Autonomic nervous system diseases | D001342 | EFO_0009532 | G90 | — | — | — | — | 1 | 1 |
| Parkinson disease | D010300 | EFO_0002508 | G20 | — | — | — | — | 1 | 1 |
| Pure autonomic failure | D054970 | — | — | — | — | 1 | 1 | ||
| Immunoglobulin light-chain amyloidosis | D000075363 | — | — | — | — | 1 | 1 | ||
| End stage liver disease | D058625 | EFO_1001311 | K72.1 | — | — | — | — | 1 | 1 |
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | — | — | — | 1 | 1 |
| Coronary disease | D003327 | — | — | — | — | 1 | 1 | ||
| Myocardial ischemia | D017202 | EFO_1001375 | I20-I25 | — | — | — | — | 1 | 1 |
| Vascular diseases | D014652 | EFO_0004264 | I77 | — | — | — | — | 1 | 1 |
| Arteriosclerosis | D001161 | EFO_0009086 | I70 | — | — | — | — | 1 | 1 |
Show 8 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | AMMONIA N 13 |
| INN | — |
| Description | Ammonia-(13)N is a (13)N-modified compound that is ammonia that has a (13)N isotope as the nitrogen atom. (13)N decays with a half-life of ten minutes to (13)C, emitting a positron. Used in diagnostic Positron Emission Tomography (PET) imaging. It has a role as a radioactive imaging agent. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | [13NH3] |
Identifiers
| PDB | — |
| CAS-ID | 34819-78-8 |
| RxCUI | 1305558 |
| ChEMBL ID | CHEMBL1201189 |
| ChEBI ID | — |
| PubChem CID | 119432 |
| DrugBank | DB09326 |
| UNII ID | — |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 159,218 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
32 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more